MERLIN TIMI-36 (metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation acute coronary syndromes treated with standard therapy.
Louis Lange, chairman and CEO of CV Therapeutics, said: “Women were very well represented in the MERLIN TIMI-36 study and these data provide important additional confirmation of the safety and efficacy we have seen with Ranexa in other clinical trials and in commercial use.”